BIOSONICS SEEKS FDA APPROVAL FOR ALTERNATIVE TO VIAGRA
BISN holds a design patent for MEGS(TM) (Male Electronic Genital Stimulator) -- a non-invasive alternative to Pfizer's (NYSE:PFE) Viagra and Vivus(TM) (NASDAQ:VVUS) Muse(TM). Based on the market demand for Pfizer's Viagra(TM), BISN has decided to proceed with its efforts to make MEGS commercially available. Jack Paller, Chief Executive Officer of BISN, explained the Company's decision, "MEGS(TM) is a non-invasive, non-pharmaceutical means of addressing male impotence. Given the public demand for a solution to male impotence, going forward with our efforts to make MEGS(TM) publicly available at this time makes sense."
BISN is involved in the development and marketing of electrotherapeutic and diagnostic devices to manage and treat several intractable medical conditions. To date, the Company holds six patents on its devices and has received FDA approval or clearance to market four of its products: Salitron(R) for dry mouth (competitor to MGI Pharmaceuticals' (NASDAQ:MOGN) product Saligen), Cystotron(TM) for urinary incontinence (competitor to EMPI Inc. (NASDAQ:EMPI) and Utah Medical), Anotron(TM) for fecal incontinence and the BIDDS(TM) glove which is a diagnostic tool. For additional information on BISN, call Raymond Bary of the NIBAR Group at 415/474-1647.
|Printer friendly Cite/link Email Feedback|
|Publication:||Biotech Equipment Update|
|Date:||Aug 1, 1998|
|Previous Article:||LASER CORP. APPROVES DPSS LASER FOR USE IN NUVOLASE 532|
|Next Article:||BURR-BROWN DEBUTS HIGH-SPEED CONVERTER FOR MEDICAL IMAGING|
|KERAVISION "RING" SELECTED FOR REVIEW UNDER FDA PILOT PROGRAM|
|Toxic herb alert.|
|Viagra causes blindness, lawsuits allege.|